Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Is there any data on denosumab use beyond 10 years from the FREEDOM Extension trial, and what do we know about the risk of atypical femoral fracture and osteonecrosis of the jaw after 10 years?
Related Questions
Is the 6-month post-operative calcium level a good indicator of patients' risk of recurrence of primary hyperparathyroidism?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
In asymptomatic patients with mild CKD, PTH independent hypercalcemia, and hypercalciuria—after excluding common causes such as hyperparathyroidism, vitamin D abnormalities, multiple myeloma, thyroid disease, vitamin A excess, and antacid use—what is the next best step in evaluation?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
When cinacalcet is used to treat hypercalcemia in primary hyperparathyroidism, does it also normalize low serum phosphorus levels?
Which method provides a more accurate assessment of hypercalciuria: 24-hour urinary calcium excretion or the spot urine calcium-to-creatinine ratio?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
Can FHH present with marked hypercalcemia (e.g., >12 mg/dL)?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
